Items tagged with Latent TB
IGRA test for latent TB infection now available through the Stop TB Partnership’s Global Drug Facility (post)
05 December 2019 I Geneva, Switzerland – The Stop TB Partnership’s Global Drug Facility (GDF) has expanded its Diagnostics Catalog by adding an IGRA (interferon-gamma release assay) test for latent TB infection. The products required to run the QuantiFERON-TB Gold Plus (QFT-Plus) IGRA are now available at a GDF-negotiated price of $15.90 per test by the manufacturer Qiagen (Hilden, Germany). This price is offered to any public sector or not-for-profit buyer in low- and middle-income countries when procuring through GDF.
Latent TB infection screening in patients with HS may be unnecessary (post)
Latent tuberculosis infection screening in patients with hidradenitis suppurativa who are treated with TNF alpha inhibitors may be unnecessary, according to a letter published in the Journal of the American Academy of Dermatology.
Latent TB infection treatment: 4 months of rifampin vs 9 months of isoniazid (post)
Treatment with 4 months of rifampin (4R) for latent tuberculosis (TB) infection was associated with substantially higher adherence, lower costs, and lower risk for severe hepatoxicity compared with 9 months of isoniazid (9H), according to study results published in the European Respiratory Journal.
Rifampicin may be safer than isoniazid in latent TB treatment (post)
In patients without a contraindication, rifampicin may be the safest treatment option for latent tuberculosis (TB) infection, according to results of a study published in the Lancet Infectious Diseases.
Short-course rifamycin-based regimens preferred for latent TB (post)
For treatment of latent tuberculosis infection (LTBI), short-course rifamycin-based regimens are preferred over longer-course isoniazid monotherapy, according to guidelines published in the Feb. 14 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
QIAGEN’s QuantiFERON®-TB Gold Plus to be adopted for latent TB testing in Nigeria (post)
QIAGEN announced that Nigeria has published guidelines recommending QuantiFERON®-TB Gold Plus (QFT®-Plus) in screening for latent TB infection as part of Nigeria’s strategy to prevent the spread of TB.
Q&A: CDC updates latent TB recommendations for first time in 20 years (post)
The CDC and National Tuberculosis Controllers Association, or NTCA, has published updated recommendations for latent tuberculosis, or LTBI, in the MMWR for the first time since 2000.
Rifapentine and isoniazid for TB prevention in patients with HIV (post)
Although tuberculosis is relatively uncommon in the United States, it remains a potent killer in less developed regions. In South Africa, TB is the number one cause of death and there is a disproportionate share of HIV-associated tuberculosis. People with HIV are more likely to progress from latent tuberculosis to active tuberculosis disease, making prevention of tuberculosis transmission a priority.
COVID-19 could accelerate activation of dormant TB (post)
The ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has thrown much of the world into disarray, with over 4 million people reported infected and well over 282,000 deaths. A new study published on the preprint server bioRxiv* in May 2020 suggests that the long-term impact of the virus could include activation of dormant bacterial infections like tuberculosis (TB).
Latent TB infection associated with very high alcohol use among people with HIV (post)
Compared with medium-level alcohol use, very high use correlated with latent tuberculosis infection among adults with HIV in Uganda, according to a cross-sectional study in Clinical Infectious Diseases.
Page 9 of 13 · Total posts: 0
←First 8 9 10 Last→